Depressive disorder and quality of life in patients with cerebral microangiopathy

The association between depressive disorder and quality of life of middle-aged patients with cerebral microangiopathy has not been fully investigated.

Aim. Study the association between the depression level and quality of life (QOL) in patients with cerebral microangiopathy.

Materials and methods. In outpatients 45–59 years old (n = 262, 42% men, 58% women) with cerebral microangiopathy and depression, the level of anxiety was assessed using the HADS-A scale, QOL — using the SF-36 questionnaire. According to the severity of depression (HADS-D subscale), the following were distinguished: group 1 (n = 116) — 8–10 points (subclinical) and group 2 (n = 146) — ≥11 points (clinical). To analyze the data used: t-test, correlation coefficient, logistic regression model; odds ratio (OR) and 95% confidence interval (CI).

Results. In group 2, the average anxiety score on the HADS-A scale was 14.3 ± 4.6 points, and for anhedonia was – 10.4 ± 4.2 points, which is statistically significantly higher than in group 1: 10.1 ± 4.2 and 7.1 ± 2.6 points, respectively (p < 0.05). The overall QOL score was statistically significantly lower in group 2: according to the physical component of health, 52.4 ± 26.5 vs. 88.8 ± 43.5 in group 1 (p < 0.05) and psychological component 38.5 ± 19.4 vs. 70.8 ± 35.8 in group 1 (p < 0.05). Depression, anxiety and anhedonia are associated with a negative effect on the overall QOL: r = −0.84 (p < 0.05), r = −0.81 (p < 0.05), r = −0.87 (p < 0.05), respectively. This association does not depend on age, obesity, type 2 diabetes mellitus: OR for depression was 2.1; 95% CI (1.8–2.4), p < 0.05; anxiety — 1.9; 95% CI (1.2–2.2), p < 0.05; anhedonia — 2.3; 95% CI (2.1–2.7), p < 0.05, respectively.

Conclusion. Clinically significant depression reduces noticeably QOL. An increase in the severity of affective symptoms leads to a deterioration in both the psychological and physical components of QOL. Decreased QOL does not depend on age, obesity, type 2 diabetes mellitus.

1. Вознесенская Т.Г. Депрессии в неврологической практике. Трудный пациент. 2003; 1(2): 26–30.

2. Воробьева О.В. Клинические особенности депрессии в общемедицинской практике (по результатам программы «Компас»). Consilium Medicum. 2004; 6(2): 154–58.

3. Краснов В.Н. Тревожно-депрессивные расстройства у пациентов первичной медицинской сети. Медвестник. 2010. URL: http://mniip-repo.ru/uploads/1332153131.pdf (дата обращения: 10.05.2020).

4. Аlеxоpоulоs G.S., Mеyеrs B.S., Yоung R.С., et al. «Vаsсulаr dеprеssiоn» hypоthеsis. Аrсh Gеn Psyсhiаtry. 1997; 54: 915–22. https://doi.org/10.1001/аrсhpsyс.1997.01830220033006 PMID: 9337771

5. Яхно Н.Н., Левин О.С., Дамулин И.В. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 2: когнитивные нарушения. Неврологический журнал. 2001; 6(3): 10–9.

6. Harwood D., Hawton K., Hope T., Jacob R. Psychiatric disorder and personality factors associated with suicide in older people: a descriptive and case-control study. Int J Geriatr Psychiatry. 2001; 16(2): 155–65. https://doi.org/10.1002/1099-1166(200102)16:2<155::aid-gps289>3.0.co;2-0 PMID: 11241720

7. Воробьева О.В. Вальдоксан в терапии депрессии в неврологической практике: результаты российского многоцентрового натуралистического исследования «Резонанс». Журнал неврологии и психиатрии им. С.С. Корсакова. 2012; 112(9): 47–51.

8. Cooper J.A., Arulpragasam A.R., Treadway M.T. Anhedonia in depression: biological mechanisms and computational models. Curr Opin Behav Sci. 2018; 22: 128–35. https://doi.org/10.1016/j.cobeha.2018.01.024 PMID: 29503842

9. Brenes G.A. Anxiety, depression, and quality of life in primary care patients. Prim Care Companion J Clin Psychiatry. 2007; 9(6): 437–43. https://doi.org/10.4088/pcc.v09n0606 PMID: 18185823

10. Wardlaw J.M., Smith E.E., Biessels G.J., et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12: 822–38. https://doi.org/10.1016/S1474-4422(13)70124-8 PMID: 23867200

11. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6): 361–70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x PMID: 6880820

12. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health S vey. Manual and interpretation guide. The Health Institute, New England Medical Center. Boston, Mass. 1993.

13. Меликян Э. Г., Гехт А. Б. Качество жизни больных э ей. Лечебное дело. 2011; 1: 1–9.

14. Бойко О.В., Татаринова М.Ю., Попова Е.В. и др. У ние показателей качества жизни больных рассеянным склерозом за 15-летний период. Журнал неврологии и психиатрии им. С.С. Корсакова. Спец выпуски. 2018; 118(8): 23–8. https://doi.org/10.17116/jnevro201811808223

15. Воробьева О.В., Фатеева В.В., Иванова Т.А. Влияние к тивных и аффективных нарушений, ассоциированных с хронической сосудистой мозговой недостаточностью, на качество жизни больных. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014; 114(8): 158–9.

16. Baker J.G., Williams A.J., Ionita C.C., et al. Cerebral small vessel disease: cognition, mood, daily functioning, and imaging findings from a small pilot sample. Dement Geriatr Cogn Dis Extra. 2012; 2(1): 169–79. https://doi.org/10.1159/000333482 PMID: 22590477

17. Амирджанова В.Н., Горячев Д.В., Коршунов Н.И. и др. П пуляционные показатели качества жизни по опроснику SF-36 (результаты многоцентрового исследования качества жизни «МИРАЖ»). Научно-практическая ревматология. 2008; 46(1): 36–48. https://doi.org/10.14412/1995-4484-2008-852

18. Захаров В.В. Депрессия при сосудистых заболеваниях г ного мозга. Эффективная фармакотерапия. Неврология. 3(31). https://umedp.ru/articles/depressiya_pri_sosudistykh_zabolevaniyakh_golovnogo_mozga.html (дата обращения 07.04.2020).

19. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci. 2008; 10(3): 291–99. PMID: 18979942

20. Höflich A., Michenthaler P., Kasper S., Lanzenberger R. Circuit Mechanisms of Reward, Anhedonia, and Depression. Int J Neuropsychopharmacol. 2019; 22(2): 105–18. https://doi.org/10.1093/ijnp/pyy081 PMID: 30239748

21. Dai L., Zhou H., Xu X., Zuo Z. Brain structural and functional changes in patients with major depressive disorder: a literature review. PeerJ. 2019; 7: e8170. https://doi.org/10.7717/peerj.8170 PMID: 31803543

22. Cuijpers P., Koole S.L., van Dijke A., et al. Psychotherapy for s clinical depression: meta-analysis. Br J Psychiatry. 2014; 205(4): 268–74. https://doi.org/10.1192/bjp.bp.113.138784 PMID: 25274315

23. Barbui C., Cipriani A., Patel V., et al. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry. 2011; 198(1): 11–1. https://doi.org/10.1192/bjp.bp.109.076448 PMID: 21200071